Ovid Therapeutics Inc. reported $1.6M of revenue over the trailing twelve months, −76% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.6M (to Q2 2026). Net income: −$34M, trailing twelve months to Q2 2026. Free cash flow: −$38M, trailing twelve months to Q4 2025. Operating margin: −5233%, trailing twelve months to Q4 2025.

OVIDOvid Therapeutics Inc.

Healthcare

$2.34+40% 1Y

$2.34

$1.2052 weeks$2.96

OVID as reported

Ovid Therapeutics Inc. reported $1.6M of revenue over the trailing twelve months, −76% on the year before. 8 reported series are charted on this page, each one as filed.

$1.6M

Revenue, trailing twelve months · to Q2 2026 · −76% against the twelve months before

Net income: −$34M
Net income · −9.7% year on year · trailing twelve months to Q2 2026
Free cash flow: −$38M
Free cash flow · trailing twelve months to Q4 2025
Operating margin: −5233%
Operating margin · trailing twelve months to Q4 2025

Details›

Every series Ryufin has for OVID, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.6M	−76%	Q2 2026
Net income	−$34M	−9.7%	Q2 2026
EPS	−$0.47	n/a	Q3 2024 · 7 quarters behind
Operating margin	−5233%	n/a	Q4 2025
Net margin	−3953%	n/a	Q4 2025
ROE	−31%	n/a	Q2 2026
ROA	−24%	n/a	Q2 2026
Free cash flow	−$38M	n/a	Q4 2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.